Primed Dendritic Cell Therapy With IFN-α and TLR Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively modulated dendritic cell antigen presentation to enhance immune stimulation for cancer treatment, with unclear mechanisms regulating DC polarization and potential downregulation of CD8+ CTLs.
Innovation Solution
A primed dendritic cell population is administered to a subject in conjunction with interferon-α (IFN-α) and TLR agonists, such as TLR-7, TLR-9, AIMp1, TLR-3, RIG-1-like receptor ligands, or cytosolic DNA receptor ligands, targeting lymphoid tissues proximal to diseased cells, and optionally with immune checkpoint inhibitors like CTLA-4 antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells are primed with antigen to enhance immune stimulation, then immune response is improved, but the mechanism of DC polarization remains unclear and may lead to downregulation of CD8+ CTLs
Solution Approach 1:
The patent applies preliminary action by pre-priming dendritic cells with specific antigens (such as tumor-associated antigens) before administration to the subject. This pre-conditioning of DCs with antigens ensures they are ready to effectively stimulate the immune system upon contact with target cells, thereby improving immune response efficacy while controlling the priming process to avoid unwanted downregulation of CD8+ CTLs
Solution Approach 2:
The patent employs parameter changes by carefully controlling the priming conditions of dendritic cells, including the type and concentration of antigens used, the culture conditions, and the maturation stimuli applied. By optimizing these parameters, the patent achieves enhanced immune stimulation while maintaining clear understanding of DC polarization mechanisms and preventing downregulation of cytotoxic T lymphocytes
2Reliability
If multiple adjuvants and agonists are used to enhance DC function, then immune stimulation is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple immunomodulatory components into a single integrated treatment approach. Specifically, it combines antigen-primed dendritic cells with selected adjuvants (such as TLR agonists) into one therapeutic composition that is administered together, thereby achieving enhanced immune stimulation while simplifying the treatment regimen compared to sequential administration of multiple separate therapies
Solution Approach 2:
The patent applies universality by using dendritic cells as a multi-functional platform that can simultaneously present multiple antigens, respond to various adjuvant stimuli, and activate different arms of the immune system (both humoral and cell-mediated immunity). This multi-functionality allows a single DC-based therapy to achieve multiple therapeutic goals without requiring multiple separate treatments
Data Source
Figure 1a~1f
Figure 2a~2f
Figure 3a~3g
AI summary
Methods of providing a targeted immune response in a subject comprising administration of a dendritic cell population are provided. In some aspects, dendritic cells are administered in conjunction with a Type I interferon (INF), a TLR-7 agonist, a TLR-9 agonist, AIMp1, a TLR-3 agonist, a retinoic acid inducible gene-1 (RIG-1)-like receptor ligand or a cytosolic DNA (CDS) receptor ligand and/or are administered to a tissue site proximal to diseased tissue. Therapeutic dendritic cell compositions are likewise provided.